Join Dr. Spyropoulos and earn 1.0 Contact Hours learning about the criteria and results from the HEP-COVID Trial that was published in JAMA in October 2021. Dr. Spyropoulos explains the mechanism of action and monitoring of DOACs versus alternate anticoagulant options and the pros and cons of each. Leave with the next steps to incorporate thrombosis prophylaxis in your nursing practice, including inpatient, post-discharge, and outpatient settings are discussed.
- Describe the cardiovascular and neurologic phenomenon that can occur post-covid-19 virus
- Identify inclusion and exclusion criteria for Hep-Covid and Prevent-HD clinical trials
- Differentiate between vaccine-induced immune thrombosis and heparin-induced thrombocytopenia
- Discuss the impact COVID-19 has had on your clinical practice/ life/work/ home environment
Additional COVID-19 Resources
Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of PCNA. PCNA is accredited by AANP as an approved provider of nurse practitioner continuing education. Provider number: 030602.